Skip to main content
MTEX
NASDAQ Life Sciences

Director Robert Toth Discloses 5.1% Stake in Mannatech via Stock Grant Amidst Financial Distress

Analysis by Wiseek.ai
Sentiment info
Positive
Importance info
8
Price
$4.75
Mkt Cap
$9.166M
52W Low
$4.665
52W High
$12.454
Market data snapshot near publication time

summarizeSummary

Director Robert Toth has disclosed beneficial ownership of 5.1% of Mannatech's common stock, acquired through an unrestricted stock grant, significantly increasing his stake in the financially distressed company.


check_boxKey Events

  • Director Acquires Significant Stake

    Robert Toth, a Director, reported beneficial ownership of 99,254 shares, representing 5.1% of Mannatech's common stock.

  • Shares Acquired via Stock Grant

    The shares were obtained through an unrestricted stock grant as part of director compensation, with no cash consideration paid by the director.

  • Increased Insider Alignment

    This substantial equity stake aligns the director's interests with shareholders, providing a strong incentive for performance improvement amidst the company's critical financial state.

  • Context of Financial Distress

    This disclosure follows recent filings indicating Mannatech's significant net loss, negative shareholders' equity, and a going concern warning.


auto_awesomeAnalysis

This Schedule 13D filing reveals that Director Robert Toth now beneficially owns 5.1% of Mannatech's outstanding common stock, totaling 99,254 shares valued at approximately $471,406. The shares were acquired as part of director compensation arrangements via an unrestricted stock grant, with no cash consideration paid by the director. This significant increase in insider ownership, especially during a period when the company is facing a going concern warning, negative shareholders' equity, and a recent CFO change, signals a strong alignment of the director's interests with those of shareholders. While not a cash investment, the substantial equity stake provides a powerful incentive for the director to contribute to the company's turnaround efforts. The stock is currently trading near its 52-week low, meaning the value of this grant is tied to a potential recovery.

At the time of this filing, MTEX was trading at $4.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.2M. The 52-week trading range was $4.67 to $12.45. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed MTEX - Latest Insights

MTEX
Apr 24, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
9
MTEX
Apr 24, 2026, 11:55 AM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
MTEX
Apr 21, 2026, 1:29 PM EDT
Filing Type: DEF 14A
Importance Score:
9
MTEX
Apr 15, 2026, 5:15 PM EDT
Source: Wiseek News
Importance Score:
9
MTEX
Apr 15, 2026, 5:14 PM EDT
Filing Type: 8-K
Importance Score:
9
MTEX
Apr 15, 2026, 5:08 PM EDT
Filing Type: 10-K
Importance Score:
10
MTEX
Apr 01, 2026, 6:47 PM EDT
Filing Type: 8-K
Importance Score:
9
MTEX
Apr 01, 2026, 6:47 PM EDT
Source: GlobeNewswire
Importance Score:
8
MTEX
Mar 24, 2026, 11:36 AM EDT
Filing Type: 8-K
Importance Score:
7